Mark Hasleton

Mark Hasleton is a seasoned professional in clinical trial financing and pharmaceuticals, currently serving as Vice President of Clinical Trial Financing at SPRIM Global Investments since April 2021. Mark co-founded CGRP Diagnostics / 428 Pharma in June 2018. Mark previously held key roles at Teva Pharmaceuticals from October 2010 to March 2018, where responsibilities included Senior Director and Global NTE Pipeline Manager, as well as Director of Ex-US Sourcing for Global Branded Products. Prior experience includes serving as EU Business Operations Manager at Bristol Myers Squibb and a Research Associate at ML Laboratories. Mark's educational background features a Master of Business Administration from Imperial College Business School and a Ph.D. in Molecular Biology from Imperial College London, complemented by a Bachelor's degree in Biochemistry and Molecular Biology from Bar-Ilan University.